EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Beta-Naphthoflavone Modulates CYP1A2 and Dp71 Gene Expression and Enhances the Long-Term Antiproliferative Effect of Sorafenib in HepG2 Cells

Patricia Nefertari Ramírez-Flores, Carlos Enrique Guerrero-Beltrán, Alain Aguirre-Vázquez, Fabiola Castorena-Torres, Beatriz Silva-Ramírez, Bulmaro Cisneros, Mario Bermúdez de León

Current Issues in Molecular Biology · 09.11.2026 · 48 (11) · 1186

DOI: 10.3390/cimb48111186 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Issues in Molecular Biology, online erschienen am 09.11.2026. Verfasst von Patricia Nefertari Ramírez-Flores und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mexican Social Security Institute.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Sorafenib (SOR) is a systemic therapy used for advanced hepatocellular carcinoma (HCC), although the therapeutic response can be limited by intrinsic or acquired resistance. β-Naphthoflavone (BNF), a synthetic flavonoid and aryl hydrocarbon receptor agonist, modulates cytochrome P450 enzymes and cancer-related pathways. In this study, we evaluated the effects of combined BNF/SOR treatment on CYP1A2 and Dp71 expression and on the viability, wound closure, invasion, and colony-forming capacity of HepG2 cells. BNF/SOR cotreatment significantly increased CYP1A2 mRNA expression, whereas no significant change in CYP1A2 protein expression was detected. SOR alone increased Dp71 mRNA expression, whereas BNF/SOR cotreatment reduced Dp71 mRNA expression relative to SOR; these changes were not detected at the protein level. SOR and BNF/SOR produced similar reductions in short-term viability and wound closure, and no statistically significant difference in invasion was detected under the conditions tested. In contrast, compared with SOR alone, BNF/SOR cotreatment resulted in a reduction in long-term colony-forming capacity. These findings reveal an association between BNF/SOR treatment, transcriptional modulation of CYP1A2 and Dp71, and reduced clonogenic capacity in HepG2 cells, without establishing causal mediation, pharmacological synergy, or reversal of sorafenib resistance.

Förderung

  • Mexican Social Security Institute

Zitieren

APA

Ramírez-Flores, P. N., Guerrero-Beltrán, C. E., Aguirre-Vázquez, A., Castorena-Torres, F., Silva-Ramírez, B., Cisneros, B., & León, M. B. D. (2026). Beta-Naphthoflavone Modulates CYP1A2 and Dp71 Gene Expression and Enhances the Long-Term Antiproliferative Effect of Sorafenib in HepG2 Cells. Current Issues in Molecular Biology, 48(11), 1186. https://doi.org/10.3390/cimb48111186

Vancouver

Ramírez-Flores PN, Guerrero-Beltrán CE, Aguirre-Vázquez A, Castorena-Torres F, Silva-Ramírez B, Cisneros B, et al. Beta-Naphthoflavone Modulates CYP1A2 and Dp71 Gene Expression and Enhances the Long-Term Antiproliferative Effect of Sorafenib in HepG2 Cells. Current Issues in Molecular Biology. 2026;48(11):1186. doi:10.3390/cimb48111186

BibTeX
@article{RamrezFlores2026,
  author = {Ramírez-Flores, Patricia Nefertari and Guerrero-Beltrán, Carlos Enrique and Aguirre-Vázquez, Alain and Castorena-Torres, Fabiola and Silva-Ramírez, Beatriz and Cisneros, Bulmaro and León, Mario Bermúdez de},
  title = {Beta-Naphthoflavone Modulates CYP1A2 and Dp71 Gene Expression and Enhances the Long-Term Antiproliferative Effect of Sorafenib in HepG2 Cells},
  journal = {Current Issues in Molecular Biology},
  year = {2026},
  volume = {48},
  number = {11},
  pages = {1186},
  doi = {10.3390/cimb48111186}
}
Kostenlos starten →